InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,722.26
(
-0.19%
)
US TECH 100
19,518.00
(
0.53%
)
Dow Jones
41,914.75
(
-0.70%
)
Brent Oil
70.95
(
-3.07%
)
Bitcoin
63,678.64
(
0.86%
)
Post# of 43374
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Preciouslife1

Send PM Follow Ignore
Followers 88
Posts 19334
Boards Moderated 4
Alias Born 11/05/2005

Preciouslife1

Re: None

Friday, 07/01/2022 2:19:00 PM

Friday, July 01, 2022 2:19:00 PM

Post# of 43374
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Humanigen (HGEN – Research Report) today and set a price target of $28.00. The company's shares closed last Thursday at $1.77, close to its 52-week low of $1.67. According to TipRanks.com, Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Bioline RX Ltd Sponsored ADR, and Lineage Cell Therapeutics. Humanigen has an analyst consensus of Moderate Buy, with a price target consensus of $28.00.

Bull-markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria .. Sir John Templeton
Make your Life a Mission .... NOT an Intermission. † §|PL1|§

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up